Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interleukin gets retinopathy risk test patent:

This article was originally published in Clinica

Executive Summary

Interleukin Genetics has gained a US patent covering a genetic test for identifying diabetics who are at increased risk for developing sight-threatening retinopathy. The patent is based on the discovery that diabetics carrying certain common variations in the IL-1 genes are more likely to develop the disease and lose their sight. By identifying which people are on a more rapid path to complications, patient-monitoring schedules may be adjusted and additional preventive measures may be applied to reduce the likelihood of serious complications, said the Waltham, Massachusetts firm. Each year, around 20,000-30,000 people lose their sight due to diabetic retinopathy, the company added.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT057928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel